CompletedPhase 4NCT04485546
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Studying Neurotrophic keratopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dompé Farmaceutici S.p.A
- Principal Investigator
- Flavio Mantelli, MD, PhDDomp Farmaceutici SpA
- Intervention
- cenegermin-bkbj(drug)
- Enrollment
- 37 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (5)
- San Diego, San Diego, California, United States
- Edgewood, Edgewood, Kentucky, United States
- Boston, Boston, Massachusetts, United States
- Saint Louis, St Louis, Missouri, United States
- Philadelphia, Philadelphia, Pennsylvania, United States
Collaborators
Dompé US
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04485546 on ClinicalTrials.govOther trials for Neurotrophic keratopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07502378Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear DeficiencyUniversity of South Florida
- RECRUITINGPHASE1, PHASE2NCT06999733A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisKrystal Biotech, Inc.
- RECRUITINGPHASE2NCT06975748A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic KeratitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE4NCT06964269Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune DiseaseToyos Clinic
- ACTIVE NOT RECRUITINGPHASE1NCT06597422A Study of STSP-0902 Ophthalmic Solution in Healthy SubjectsStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE2NCT05927428Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic KeratitisBRIM Biotechnology Inc.
- RECRUITINGPHASE3NCT05555589Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2ReGenTree, LLC
- ACTIVE NOT RECRUITINGPHASE4NCT06947850DOMPE -MT Neurotrophic KeratitisToyos Clinic